+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease CKD and metabolic acidosis. This phase 3 study compares veverimer against a placebo to better understand its impact on these conditions. The study is sponsored by Renibus Therapeutics, Inc. and uses a randomized, double-blind, placebo-controlled design to ensure reliable results. Participants are randomly assigned to receive either 9 g of veverimer twice daily or a placebo twice daily. The study lasts up to 168 days, during which the effects of the treatments on serum bicarbonate levels and physical performance, specifically the Sit-to-Stand 5 times test, are assessed. The trial also monitors safety and tolerability through treatment-emergent adverse events throughout the study period. During the study, participants will have regular visits from screening through Day 168 where various assessments take place. These include measuring serum bicarbonate concentration, physical performance tests, frailty and muscle mass evaluations, and safety checks. Participants are expected to maintain consistent dietary habits and stable doses of any oral alkali therapies during the trial. The total length of participation extends through the 168-day treatment and evaluation period.

Age: 18Years +All GendersPhase 3
28 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.

Age: 6Years - 17YearsAll GendersPhase 3
93 locations
S

Actively Recruiting

Researchers are studying type 2 diabetes, a condition where the body cannot properly use insulin to control blood sugar, leading to complications like heart disease, kidney failure, and nerve damage. This research evaluates a botanical extract called HP-211, which has shown promise in lab and animal studies for helping insulin work better to lower blood sugar and insulin levels. The goal is to see if HP-211 can reduce blood glucose and insulin responses in people with type 2 diabetes, especially those with insulin resistance. Participants will be randomly assigned to receive different doses of HP-2110.98 grams, 1.96 grams, or 2.94 grams twice dailyor a placebo, taken as tablets in the morning and evening for 90 days, preferably at least 60 minutes before meals. The study includes a dose-ranging phase to test safety and proof of concept by comparing these doses. Researchers will monitor changes in blood sugar control and insulin levels during the treatment period. Throughout the trial, participants will have blood tests to measure hemoglobin A1c HbA1c, which reflects average blood sugar over time, as well as fasting blood glucose and self-monitored blood glucose profiles. Safety assessments will track adverse events, body weight, and quality of life related to diabetes treatment. The study lasts 12 weeks of treatment plus 4 weeks of withdrawal monitoring, with ongoing evaluations to assess the effects and safety of HP-211 on blood sugar control.

Age: 18Years +All GendersPhase 2
25 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a bivalent vaccine candidate designed to protect adults aged 60 years and older against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV. This Phase 12, randomized, observer-blind, placebo-controlled study involves about 2400 participants and aims to assess the vaccines ability to trigger immune responses and monitor its safety. While several RSV vaccines are approved, there is currently no vaccine for preventing HMPV in older adults. Participants will be assigned to one of 11 groups, receiving different doses of the RSVHMPV vaccine, placebo, or one of four control vaccines. The study includes six dose levels of the RSVHMPV vaccine with predefined antigen ratios. Each participant will be followed for approximately 12 months to allow comprehensive evaluation. The study is conducted across multiple centers and uses a parallel group design. During the study, participants will have blood samples taken at baseline, Day 29, and at 3, 6, 9, and 12 months to measure neutralizing antibodies and immunoglobulin G concentrations against RSV and HMPV. Safety will be monitored through reporting of adverse events shortly after vaccination, for several days post-vaccination, and up to six months or throughout the 12-month study period. Biological tests and medical assessments will also be performed to ensure participant safety and collect detailed data on immune response.

Age: 60Years +All GendersPhase 1Phase 2
50 locations
R

Actively Recruiting

This research evaluates the drug clofutriben in patients with type 2 diabetes who have elevated cortisol levels. The study aims to understand how different doses of clofutriben affect blood sugar control and to find one or more doses suitable for further testing. It is a two-part, multicenter, randomized, double-blind trial designed to assess clofutribens impact compared to a placebo. The trial has two parts. Part 1 is a screening phase lasting about 5 to 9 weeks, including initial eligibility assessment, a dexamethasone suppression test, and further evaluations. Participants who qualify then enter Part 2, where they are randomly assigned to receive one of four doses of clofutriben or a placebo, taken daily by mouth for 24 weeks. After treatment, there is a follow-up phone call 4 weeks later. Participants will undergo various assessments including blood tests for cortisol and glycated hemoglobin HbA1c to measure effects on cortisol levels and blood sugar control. The main outcomes include changes in HbA1c and cortisol levels after 24 weeks of treatment. Safety and other blood sugar measures will also be monitored. The total involvement may last several months including screening, treatment, and follow-up.

Age: 18Years +All GendersPhase 2
61 locations